Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 20.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 294,391 shares of the life sciences company’s stock after purchasing an additional 49,379 shares during the quarter. BNP Paribas Financial Markets’ holdings in Illumina were worth $38,392,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Primecap Management Co. CA boosted its position in Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after acquiring an additional 1,997,010 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after purchasing an additional 1,118,747 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Illumina in the second quarter valued at $77,628,000. Massachusetts Financial Services Co. MA increased its stake in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after purchasing an additional 631,294 shares during the last quarter. Finally, Federated Hermes Inc. lifted its position in Illumina by 511.7% during the second quarter. Federated Hermes Inc. now owns 530,439 shares of the life sciences company’s stock worth $55,367,000 after buying an additional 443,720 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Robert W. Baird increased their price target on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Morgan Stanley reissued an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. JPMorgan Chase & Co. increased their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and boosted their price target for the company from $120.00 to $154.00 in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Stock Up 1.0 %

ILMN stock opened at $144.36 on Friday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The firm has a 50 day simple moving average of $141.62 and a 200-day simple moving average of $125.66. The company has a market capitalization of $22.90 billion, a P/E ratio of -14.49 and a beta of 1.13. Illumina, Inc. has a twelve month low of $93.51 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.33 EPS. On average, equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.